Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease
- 123 Downloads
Spinocerebellar ataxias are dominantly inherited neurodegenerative disorders with no disease-modifying treatment. We previously identified the selective serotonin reuptake inhibitor citalopram as a safe and effective drug to be repurposed for Machado-Joseph disease. Pre-symptomatic treatment of transgenic (CMVMJD135) mice strikingly ameliorated mutant ataxin-3 (ATXN3) pathogenesis. Here, we asked whether citalopram treatment initiated at a post-symptomatic age would still show efficacy. We used a cohort of CMVMJD135 mice that shows increased phenotypic severity and faster disease progression (CMVMJD135hi) compared to the mice used in the first trial. Groups of hemizygous CMVMJD135hi mice were orally treated with citalopram. Behavior, protein analysis, and pathology assessment were performed blindly to treatment. Our results show that even when initiated after symptom onset, treatment of CMVMJD135hi mice with citalopram ameliorated motor coordination and balance, attenuating disease progression, albeit to a lesser extent than that seen with pre-symptomatic treatment initiation. There was no impact on ATXN3 aggregation, which contrasts with the robust reduction in ATXN3-positive inclusions observed in CMVMJD135 mice, when treated pre-symptomatically. Post-symptomatic treatment of CMVMJD135hi mice revealed, however, a limited neuroprotective effect by showing a tendency to repair cerebellar calbindin staining, and to increase the number of motor neurons and of NeuN-positive cells in certain brain regions. While supporting that early initiation of treatment with citalopram leads to a marked increase in efficacy, these results strengthen our previous observation that modulation of serotonergic signaling by citalopram is a promising therapeutic approach for Machado-Joseph disease even after symptom onset.
KeywordsSpinocerebellar ataxia type 3 Selective serotonin reuptake inhibitor Citalopram Post-symptomatic treatment Transgenic model
Selective serotonin reuptake inhibitor.
We are grateful to the members of the Maciel laboratory for sharing reagents and for critical analysis of the data and discussions on the manuscript. We thank members of the Morimoto lab for critical analysis of the results and figures. We also thank H. Lundbeck A/S for providing citalopram hydrobromide and Dr. Karina Fog for scientific discussions. We are grateful to Maria do Carmo Costa for critical review of the manuscript.
SE, SO, AT-C, and PM contributed to the research project conception and organization. SE, SO, SD-S, DG-C, and AT-C performed the experiments. SE, SO, SD-S, and AT-C contributed to the statistical analysis design. SE, SO, and SD-S performed the statistical analysis. SE and AT-C wrote the first draft of the article. SO, SD-S, DG-C, AT-C, and PM reviewed and criticized the manuscript. All authors read and approved the final manuscript.
This work has been funded by the European Regional Development Funds (FEDER), through the Competitiveness Factors Operational Programme (COMPETE), and by National funds, through the Foundation for Science and Technology (FCT), under the scope of the project POCI-01-0145-FEDER-007038. This article has been developed under the scope of the project NORTE-01-0145-FEDER-000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the FEDER. This work was also supported by FCT and COMPETE through the projects [PTDC/SAU-GMG/112617/2009] (to PM) and [EXPL/BIM-MEC/0239/2012] (to AT-C), by FCT through the project [POCI-01-0145-FEDER-016818 (PTDC/NEU-NMC/3648/2014)] (to PM), by National Ataxia foundation (to PM and to AT-C), and by Ataxia UK (to PM). SE, SD-S, SO, and AT-C were supported by the FCT individual fellowships, SFRH/BD/78554/2011, SFRH/BD/78388/2011, PD/BD/127818/2016, and SFRH/BPD/102317/2014, respectively. FCT fellowships are co-financed by POPH, QREN, Governo da República Portuguesa, and EU/FSE.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 12.Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF (2010) Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 22(1):8–18. https://doi.org/10.1176/appi.neuropsych.22.1.8 CrossRefPubMedGoogle Scholar
- 14.Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G et al (2011) Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 108(36):14968–14973. https://doi.org/10.1073/pnas.1107411108 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V et al (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol 234(2):405–416. https://doi.org/10.1016/j.expneurol.2012.01.008 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL et al (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 30(3):312–322. https://doi.org/10.1016/j.nbd.2008.01.015 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Teixeira-Castro A, Jalles A, Esteves S, Kang S, da Silva Santos L, Silva-Fernandes A, Neto MF, Brielmann RM et al (2015) Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 138(11):3221–3237. https://doi.org/10.1093/brain/awv262 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Ashraf NS, Duarte-Silva S, Shaw ED, Maciel P, Paulson HL, Teixeira-Castro A, do Carmo Costa M (2018) Citalopram reduces aggregation of ATXN3 in a YAC transgenic mouse model of Machado-Joseph disease. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1331-2
- 22.Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, Amorim M, Soares-Cunha C, Oliveira P, Thirstrup K, Teixeira-Castro A et al (2014) Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics 11:433–449. https://doi.org/10.1007/s13311-013-0255-9 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Silva-Fernandes A, Costa Mdo C, Duarte-Silva S, Oliveira P, Botelho CM, Martins L, Mariz JA, Ferreira T et al (2010) Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis 40(1):163–176. https://doi.org/10.1016/j.nbd.2010.05.021 CrossRefPubMedGoogle Scholar
- 33.Tatum MC, Ooi FK, Chikka MR, Chauve L, Martinez-Velazquez LA, Steinbusch HW, Morimoto RI, Prahlad V (2015) Neuronal serotonin release triggers the heat shock response in C. elegans in the absence of temperature increase. Curr Biol 25(2):163–174. https://doi.org/10.1016/j.cub.2014.11.040 CrossRefPubMedGoogle Scholar
- 37.Oostland M, van Hooft JA (2013) The role of serotonin in cerebellar development. Neuroscience 248:201–212. https://doi.org/10.1016/j.neuroscience.2013.05.029 CrossRefPubMedGoogle Scholar
- 39.Costa MDC, Ashraf NS, Fischer S, Yang Y, Schapka E, Joshi G, McQuade TJ, Dharia RM et al (2016) Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain 139(11):2891–2908. https://doi.org/10.1093/brain/aww228 CrossRefPubMedPubMedCentralGoogle Scholar